{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T04:37:28Z","timestamp":1782967048266,"version":"3.54.5"},"reference-count":64,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,1,3]],"date-time":"2019-01-03T00:00:00Z","timestamp":1546473600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012603","name":"Startup Research Fund of Zhengzhou University","doi-asserted-by":"publisher","award":["1521331002"],"award-info":[{"award-number":["1521331002"]}],"id":[{"id":"10.13039\/501100012603","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2018M630840"],"award-info":[{"award-number":["2018M630840"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011247","name":"State Key Laboratory of Pharmaceutical Biotechnology","doi-asserted-by":"publisher","award":["KF-GN-201902"],"award-info":[{"award-number":["KF-GN-201902"]}],"id":[{"id":"10.13039\/501100011247","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773562"],"award-info":[{"award-number":["81773562"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81703326"],"award-info":[{"award-number":["81703326"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21403200"],"award-info":[{"award-number":["21403200"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81430085"],"award-info":[{"award-number":["81430085"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012663","name":"Henan Province University Innovation Talents Support Program","doi-asserted-by":"publisher","award":["161100310100"],"award-info":[{"award-number":["161100310100"]}],"id":[{"id":"10.13039\/501100012663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012663","name":"Henan Province University Innovation Talents Support Program","doi-asserted-by":"publisher","award":["182102310123"],"award-info":[{"award-number":["182102310123"]}],"id":[{"id":"10.13039\/501100012663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.apsb.2019.01.001","type":"journal-article","created":{"date-parts":[[2019,1,4]],"date-time":"2019-01-04T21:06:57Z","timestamp":1546636017000},"page":"794-808","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"title":["Development of the triazole-fused pyrimidine derivatives as highly potent and reversible inhibitors of histone lysine specific demethylase 1 (LSD1\/KDM1A)"],"prefix":"10.1016","volume":"9","author":[{"given":"Zhonghua","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongrui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhizheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengzhi","family":"Suo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taoqian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2019.01.001_bib1","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nrm3327","article-title":"Molecular mechanisms and potential functions of histone demethylases","volume":"13","author":"Kooistra","year":"2012","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.apsb.2019.01.001_bib2","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.apsb.2018.06.001","article-title":"N6-methyladenosine modification: a novel pharmacological target for anti-cancer drug development","volume":"8","author":"Niu","year":"2018","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2019.01.001_bib3","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nrg3173","article-title":"Histone methylation: a dynamic mark in health, disease and inheritance","volume":"13","author":"Greer","year":"2012","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.apsb.2019.01.001_bib4","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1016\/j.bmc.2011.01.046","article-title":"Inhibitors of histone demethylases","volume":"19","author":"Lohse","year":"2011","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.apsb.2019.01.001_bib5","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1021\/acs.jmedchem.5b01758","article-title":"Recent progress in histone demethylase inhibitors","volume":"59","author":"McAllister","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2019.01.001_bib6","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/0006-291X(73)91383-1","article-title":"Enzymatic demethylation of calf thymus histones","volume":"51","author":"Paik","year":"1973","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.apsb.2019.01.001_bib7","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.cell.2004.12.012","article-title":"Histone demethylation mediated by the nuclear amine oxidase homolog LSD1","volume":"119","author":"Shi","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2019.01.001_bib8","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature04020","article-title":"LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription","volume":"437","author":"Metzger","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2019.01.001_bib9","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.cell.2006.12.038","article-title":"Histone methylation-dependent mechanisms impose ligand dependency for gene activation by nuclear receptors","volume":"128","author":"Garcia-Bassets","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2019.01.001_bib10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/ng.268","article-title":"The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation","volume":"41","author":"Wang","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.apsb.2019.01.001_bib11","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nature05987","article-title":"DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA","volume":"448","author":"Ooi","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2019.01.001_bib12","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature08315","article-title":"KDM1B is a histone H3K4 demethylase required to establish maternal genomic imprints","volume":"461","author":"Ciccone","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2019.01.001_bib13","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nature06092","article-title":"p53 is regulated by the lysine demethylase LSD1","volume":"449","author":"Huang","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2019.01.001_bib14","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.molcel.2010.06.006","article-title":"Lysine methylation regulates E2F1-induced cell death","volume":"39","author":"Kontaki","year":"2010","journal-title":"Mol Cell"},{"key":"10.1016\/j.apsb.2019.01.001_bib15","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.molcel.2007.02.025","article-title":"Heterochromatin formation in Drosophila is initiated through active removal of H3K4 methylation by the LSD1 homolog SU(VAR)3-3","volume":"26","author":"Rudolph","year":"2007","journal-title":"Mol Cell"},{"key":"10.1016\/j.apsb.2019.01.001_bib16","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1530\/REP-06-0251","article-title":"Temporal expression of factors involved in chromatin remodeling and in gene regulation during early bovine in vitro embryo development","volume":"133","author":"McGraw","year":"2007","journal-title":"Reproduction"},{"key":"10.1016\/j.apsb.2019.01.001_bib17","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.cub.2007.03.068","article-title":"Mutation of Drosophila Lsd1 disrupts H3-K4 methylation, resulting in tissue-specific defects during development","volume":"17","author":"Di Stefano","year":"2007","journal-title":"Curr Biol"},{"key":"10.1016\/j.apsb.2019.01.001_bib18","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.molmed.2007.07.003","article-title":"Chromatin remodeling and cancer, part I: covalent histone modifications","volume":"13","author":"Wang","year":"2007","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.apsb.2019.01.001_bib19","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/ncb3326","article-title":"C\/EBP\u03b1 creates elite cells for iPSC reprogramming by upregulating Klf4 and increasing the levels of Lsd1 and Brd4","volume":"18","author":"Di Stefano","year":"2016","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.apsb.2019.01.001_bib20","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2217\/epi.15.9","article-title":"KDM1 histone lysine demethylases as targets for treatments of oncological and neurodegenerative disease","volume":"7","author":"Maes","year":"2015","journal-title":"Epigenomics"},{"key":"10.1016\/j.apsb.2019.01.001_bib21","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s10142-011-0246-z","article-title":"Emerging roles of epigenetic mechanisms in Parkinson\u05f3s disease","volume":"11","author":"Habibi","year":"2011","journal-title":"Funct Integr Genom"},{"key":"10.1016\/j.apsb.2019.01.001_bib22","doi-asserted-by":"crossref","first-page":"11341","DOI":"10.1158\/0008-5472.CAN-06-1570","article-title":"Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence","volume":"66","author":"Kahl","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2019.01.001_bib23","doi-asserted-by":"crossref","first-page":"100","DOI":"10.4161\/epi.5.2.10778","article-title":"Epigenetic regulation of androgen receptor signaling in prostate cancer","volume":"5","author":"Gao","year":"2010","journal-title":"Epigenetics"},{"key":"10.1016\/j.apsb.2019.01.001_bib24","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.humpath.2009.08.007","article-title":"H3K4 dimethylation in hepatocellular carcinoma is rare compared with other hepatobiliary and gastrointestinal carcinomas and correlates with expression of the methylase Ash2 and the demethylase LSD1","volume":"41","author":"Magerl","year":"2010","journal-title":"Hum Pathol"},{"key":"10.1016\/j.apsb.2019.01.001_bib25","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.cell.2009.05.050","article-title":"LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer","volume":"138","author":"Wang","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2019.01.001_bib26","doi-asserted-by":"crossref","first-page":"e35065","DOI":"10.1371\/journal.pone.0035065","article-title":"Over-expression of LSD1 promotes proliferation, migration and invasion in non-small cell lung cancer","volume":"7","author":"Lv","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2019.01.001_bib27","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1158\/0008-5472.CAN-08-1735","article-title":"Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy","volume":"69","author":"Schulte","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2019.01.001_bib28","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ccr.2012.03.027","article-title":"Breaking the LSD1\/KDM1A addiction: therapeutic targeting of the epigenetic modifier in AML","volume":"21","author":"Lokken","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.apsb.2019.01.001_bib29","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1128\/MCB.02030-07","article-title":"Transrepressive function of TLX requires the histone demethylase LSD1","volume":"28","author":"Yokoyama","year":"2008","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.apsb.2019.01.001_bib30","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/bjc.2013.364","article-title":"LSD1-mediated epigenetic modification contributes to proliferation and metastasis of colon cancer","volume":"109","author":"Ding","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.apsb.2019.01.001_bib31","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nrd4154","article-title":"Histone lysine demethylases as targets for anticancer therapy","volume":"12","author":"H\u00f8jfeldt","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2019.01.001_bib32","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1038\/onc.2016.395","article-title":"Novel KDM1A inhibitors induce differentiation and apoptosis of glioma stem cells via unfolded protein response pathway","volume":"36","author":"Sareddy","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.apsb.2019.01.001_bib33","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/onc.2017.353","article-title":"LSD1 promotes S-phase entry and tumorigenesis via chromatin co-occupation with E2F1 and selective H3K9 demethylation","volume":"37","author":"He","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.apsb.2019.01.001_bib34","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1182\/blood.V128.22.4060.4060","article-title":"Safety, phamacokinetics (PK), pharmacodynamics (PD) and preliminary activity in acute leukemia of Ory-1001, a first-in-Class inhibitor of lysine-specific histone demethylase 1A (LSD1\/KDM1A): initial results from a first-in-human phase 1 study","volume":"128","author":"Somervaille","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2019.01.001_bib35","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2217\/epi-2015-0002","article-title":"TCPs: privileged scaffolds for identifying potent LSD1 inhibitors for cancer therapy","volume":"8","author":"Zheng","year":"2016","journal-title":"Epigenomics"},{"key":"10.1016\/j.apsb.2019.01.001_bib36","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.1158\/1538-7445.AM2016-4704","article-title":"The evaluation of INCB059872, an FAD-directed inhibitor of LSD1, in preclinical models of human small cell lung cancer","volume":"76","author":"Lee","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2019.01.001_bib37","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.4155\/fmc-2017-0068","article-title":"Advances toward LSD1 inhibitors for cancer therapy","volume":"9","author":"Fu","year":"2017","journal-title":"Future Med Chem"},{"key":"10.1016\/j.apsb.2019.01.001_bib38","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/med.21334","article-title":"Reversible inhibitors of LSD1 as therapeutic agents in acute myeloid leukemia: clinical significance and progress to date","volume":"35","author":"Mould","year":"2015","journal-title":"Med Res Rev"},{"key":"10.1016\/j.apsb.2019.01.001_bib39","doi-asserted-by":"crossref","first-page":"9496","DOI":"10.1021\/jm400870h","article-title":"High-throughput virtual screening identifies novel N\u2032-(1-phenylethylidene)-benzohydrazides as potent, specific, and reversible LSD1 inhibitors","volume":"56","author":"Sorna","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2019.01.001_bib40","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1039\/c3md00226h","article-title":"Development and evaluation of selective, reversible LSD1 inhibitors derived from fragments","volume":"4","author":"Hitchin","year":"2013","journal-title":"MedChemComm"},{"key":"10.1016\/j.apsb.2019.01.001_bib41","doi-asserted-by":"crossref","first-page":"7984","DOI":"10.1021\/acs.jmedchem.7b00462","article-title":"Development of (4-cyanophenyl)glycine derivatives as reversible inhibitors of lysine specific demethylase 1","volume":"60","author":"Mould","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2019.01.001_bib42","unstructured":"Johnson NW. The identification of GSK2879552, a mechanism based irreversible inhibitor of the histone lysine demethylase LSD1. In: XXIV EFMC international symposium on medicinal chemistry. Manchester, UK. Cambridge: Royal society of chemsitry; Aug 28Sep 1 2016."},{"key":"10.1016\/j.apsb.2019.01.001_bib43","doi-asserted-by":"crossref","first-page":"8543","DOI":"10.1021\/jm401002r","article-title":"Triazole-dithiocarbamate based selective lysine specific demethylase 1 (LSD1) inactivators inhibit gastric cancer cell growth, invasion, and migration","volume":"56","author":"Zheng","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2019.01.001_bib44","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1021\/acs.jmedchem.5b00037","article-title":"Design, synthesis, and structureactivity relationship of novel LSD1 inhibitors based on pyrimidine-thiourea hybrids as potent, orally active antitumor agents","volume":"58","author":"Ma","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2019.01.001_bib45","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1039\/C4MD00031E","article-title":"Synthesis and biological evaluation of coumarin-1,2,3-triazole-dithiocarbamate hybrids as potent LSD1 inhibitors","volume":"5","author":"Ye","year":"2014","journal-title":"MedChemComm"},{"key":"10.1016\/j.apsb.2019.01.001_bib46","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1021\/acsmedchemlett.6b00423","article-title":"Discovery of [1,2,3]triazolo[4,5-d]pyrimidine derivatives as novel LSD1 inhibitors","volume":"8","author":"Li","year":"2017","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.apsb.2019.01.001_bib47","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.ejmech.2016.10.021","article-title":"Design, synthesis and biological evaluation of [1,2,4]triazolo[1,5-a]pyrimidines as potent lysine specific demethylase 1 (LSD1\/KDM1A) inhibitors","volume":"125","author":"Wang","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2019.01.001_bib48","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.ejmech.2016.10.022","article-title":"Design, synthesis and biological evaluation of [1,2,3]triazolo[4,5-d]pyrimidine derivatives possessing a hydrazone moiety as antiproliferative agents","volume":"124","author":"Li","year":"2016","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2019.01.001_bib49","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1021\/jo070246n","article-title":"Isothiocyanates from tosyl chloride mediated decomposition of in situ generated dithiocarbamic acid salts","volume":"72","author":"Wong","year":"2007","journal-title":"J Org Chem"},{"key":"10.1016\/j.apsb.2019.01.001_bib50","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2174\/0929867053363540","article-title":"Bioisosterism: a useful strategy for molecular modification and drug design","volume":"12","author":"Lima","year":"2005","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.apsb.2019.01.001_bib51","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.drudis.2006.12.003","article-title":"Scaffold selection and scaffold hopping in lead generation: a medicinal chemistry perspective","volume":"12","author":"Zhao","year":"2007","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.apsb.2019.01.001_bib52","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1021\/jm901137j","article-title":"New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays","volume":"53","author":"Baell","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2019.01.001_bib53","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/med.21354","article-title":"Potential clinical uses of CDK inhibitors: lessons from synthetic lethality screens","volume":"35","author":"Vyme\u02c7talov\u00e1","year":"2015","journal-title":"Med Res Rev"},{"key":"10.1016\/j.apsb.2019.01.001_bib54","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1016\/j.bmcl.2014.02.075","article-title":"Purine derivatives as potent Bruton\u05f3s tyrosine kinase (BTK) inhibitors for autoimmune diseases","volume":"24","author":"Shi","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2019.01.001_bib55","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s00432-011-1039-4","article-title":"The CDK inhibitors in cancer research and therapy","volume":"137","author":"Cicenas","year":"2011","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.apsb.2019.01.001_bib56","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccr.2012.03.014","article-title":"The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells","volume":"21","author":"Harris","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.apsb.2019.01.001_bib57","doi-asserted-by":"crossref","first-page":"85085","DOI":"10.18632\/oncotarget.18564","article-title":"Upregulation of CD11b and CD86 through LSD1 inhibition promotes myeloid differentiation and suppresses cell proliferation in human monocytic leukemia cells","volume":"8","author":"Fang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.apsb.2019.01.001_bib58","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13045-016-0252-7","article-title":"Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia","volume":"9","author":"Feng","year":"2016","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.apsb.2019.01.001_bib59","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1158\/0008-5472.CAN-15-2333","article-title":"Pharmacological inhibition of the histone lysine demethylase KDM1A suppresses the growth of multiple acute myeloid leukemia subtypes","volume":"76","author":"McGrath","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2019.01.001_bib60","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/nm.2661","article-title":"Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia","volume":"18","author":"Schenk","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2019.01.001_bib61","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1038\/leu.2014.119","article-title":"Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells","volume":"28","author":"Fiskus","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.apsb.2019.01.001_bib62","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1021\/ja909996p","article-title":"Comparative analysis of small molecules and histone substrate analogues as LSD1 lysine demethylase inhibitors","volume":"132","author":"Culhane","year":"2010","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.apsb.2019.01.001_bib63","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1021\/ja01318a036","article-title":"The determination of enzyme dissociation constants","volume":"56","author":"Lineweaver","year":"1934","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.apsb.2019.01.001_bib64","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1002\/ijc.27555","article-title":"Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor","volume":"131","author":"Willmann","year":"2012","journal-title":"Int J Cancer"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383518309080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383518309080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T16:41:10Z","timestamp":1761928870000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383518309080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":64,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S2211383518309080"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2019.01.001","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of the triazole-fused pyrimidine derivatives as highly potent and reversible inhibitors of histone lysine specific demethylase 1 (LSD1\/KDM1A)","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2019.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}